Baxter (NYSE:BAX) today presented data from 24 different abstracts on treatments for end-stage kidney disease, touting 8 that covered its Theranova dialyser, indicated for treating chronic and acute renal failure.
The study data was presented at the European Renal Association and European Dialysis and Transplant Association’s 53rd Congress this week.
”Regardless of where dialysis therapy is performed – in a hospital, in a centre or at home – Baxter is actively researching unique solutions, introducing innovative technologies and elevating scientific exchange to advance renal care. Baxter presented data at ERA-EDTA that examined a range of new technologies and therapies to increase the quality of patient care, as well as enhance awareness and access to different modalities,” medical affairs veep Dr. Dheerendra Kommala said in a press release.
Baxter presented data from a study that indicated haemodialysis with its Theranova MCO dialyser provided higher mean overall toxin clearance compared with current-market high-flux dialysers, and that its Theranova MCO HD more efficiently removed middle molecules with moderate albumin loss when compared to high-flux and haemodiafiltration.
The company said the results indicated that treatment with its Theranova MCO dialyzer provides similar outcomes to the use of haemodiafiltration at a lower cost.
Additional abstracts presented at the conference analyzed new tech and practices across chronic renal therapies, including a novel examination of the flexibility in prescribing options of nocturnal home high dose HD to normalize serum phosphorus concentrations.
Earlier this month, Baxter appeared to be the frontrunner to buy India’s Gland Pharma for as much as $1.2 billion, according to the Economic Times.
Hyderabad-based Gland, which is partially owned by private equity giant KKR, is a contract manufacturer of injectables. KKR bought a 40% stake for $191 million in November 2013; founders led by Ravi Penmetsa own the majority stake.
Baxter and Chinese conglomerate Fosun Group were the only bidders when the deadline came, after potential suitors Torrent Pharma, PE buyout fund Advent, Perrigo and Dr Reddy’s stayed out of the running, the newspaper reported.